This webinar concluded on Nov 21st 2023

Parkinson's disease, a life-altering condition, profoundly impacts individuals, influencing daily activities. Ongoing strides in drug development research offer hope for improved treatments, underscoring the importance of sustained efforts to enhance the lives of those affected.

Join us for an enlightening journey through the ever-evolving landscape of Parkinson's disease drug development, with a special emphasis on the pivotal role of imaging biomarkers in clinical trial endpoints.

This unique opportunity allows you to explore the changing dynamics in drug development, advanced imaging techniques, and the intricacies of Parkinson's disease research.

Topics we’ll cover:

• The Changing Landscape of Parkinson's Drug Development
• Imaging and Analysis: A Focus on Alpha-synuclein and DAT SPECT Imaging
• Emerging Frontiers:   Advanced MRI and PET Techniques
• Navigating Challenges in Integrating Imaging into Clinical Trials
• Opportunities for Future Developments
• Your Questions Answered

Don't miss out on this unique opportunity to delve into the intricate world of Parkinson's disease research and gain invaluable insights. Our experts, Ken Marek and Richard Manber, will guide you through a knowledge-packed session.

About the speakers

Kenneth Marek, President, Institute for Neurodegenerative Disorders

Dr. Kenneth Marek, MD, is the President and Senior Scientist at the Institute for Neurodegenerative Disorders. His research focuses on early detection biomarkers, disease progression, and treatments for Parkinson's, Alzheimer's, and related neurodegenerative disorders, particularly in vivo neuroreceptor imaging. He leads international studies, serves as a special advisor to The Michael J. Fox Foundation, and received the Robert A. Pritzker Prize for Leadership in Parkinson's Research. Dr. Marek earned his MD from Yale, trained at Johns Hopkins, and completed a neurochemistry post-doctoral fellowship at the Institute of Neurology, London.

Richard Manber – Biomarker Science Manager, IXICO

Dr. Richard Manber currently works as Biomarker Science Manager at IXICO, providing neuroimaging expertise for CNS clinical trials, currently working in clinical trials across a range of phases 1-3 in Alzheimer’s, Parkinson's, Huntington’s disease, and more. He gained a master’s degree from the University of Bristol in Engineering Maths, before completing his Ph.D. in 2016 at University College London in Medical Physics, with a specialization in image acquisition and reconstruction for motion correction in simultaneous PET/MRI, funded by Siemens Healthcare. He has co-authored recent papers in Nature Medicine, the Journal of Nuclear Medicine, and JAMA Neurology, and has worked as the science lead at IXICO in large studies such as AMYPAD and GAP.

 

---